Screening Examination of Premature Infants for Retinopathy of Prematurity

One-Week-or-Less Follow-up

• Zone I: immature vascularization, no ROP;

• Zone I: stage 1 or stage 2 ROP;

• Immature retina extending into posterior zone II, near the boundary of zone I–zone II;

• Suspected presence of AP-ROP; and

• Stage 3 ROP, zone I requires treatment, not observation.

One- to 2-Week Follow-up

• Posterior zone II: immature vascularization;

• Zone II: stage 2 ROP; and

• Zone I: unequivocally regressing ROP.

Two-Week Follow-up

• Zone II: stage 1 ROP;

• Zone II: no ROP, immature vascularization; and

• Zone II: unequivocally regressing ROP.

Two- to 3-Week Follow-up

• Zone III: stage 1 or 2 ROP; and

• Zone III: regressing ROP.

• 5. The termination of acute retinal screening examinations should be based on age and retinal ophthalmoscopic findings.¹³ Findings in which is it suggested that examinations can be terminated include the following:

  • Full retinal vascularization in close proximity to the ora serrata for 360°, that is, the normal distance found in mature retina between the end of vascularization and the ora serrata. This criterion should also be used for all cases treated for ROP solely with anti–vascular endothelial growth factor (VEGF) injectable medications.

  • Zone III retinal vascularization attained without previous zone I or II ROP (if there is examiner doubt about the zone or if the postmenstrual age is less than 35 weeks, confirmatory examinations may be warranted).

  • Postmenstrual age of 45 weeks and no type 1 ROP (previously called “prethreshold”) disease (defined as stage 3 ROP in zone II, any ROP in zone I) or worse ROP is present.

  • If anti-VEGF injectable medications were used to cause regression of the ROP, postmenstrual age of at least 65 weeks, because this treatment alters the natural history of this disease. Very late recurrences of proliferative ROP have been reported,^19–21 so caution and clinical judgment are required to determine when surveillance can be safely terminated in individual cases. Infants treated with anti-VEGF medications need particularly close follow-up during the time of highest risk for disease reactivation, between postmenstrual age 45 to 55 weeks.

  • Regression of ROP²² (care must be taken to be sure that there is no abnormal vascular tissue present that is capable of reactivation and progression in zone II or III).

• 6. The use of digital photographic retinal images that are captured and sent for remote interpretation is a developing alternative approach to ophthalmoscopic ROP screening^23,24; however, few outcome comparisons between large-scale operational digital-imaging systems with remote interpretation versus binocular indirect ophthalmoscopy have been published.²⁵ Nevertheless, some neonatal centers are conducting remote ROP screening for infants still in the hospital.^23,24 At a minimum, programs that use this method should comply with the timing and other recommendations outlined in the preceding guidelines as well as have capacity for timely bedside examinations if images are ambiguous or be able to promptly transfer to a hospital that can provide this examination. Protocol modifications may be required to allow for additional time for communication, processing, transportation, or other logistical issues,^26,27 with no time added to the timing noted below for treatment. Captured images and their interpretations should be incorporated into the permanent medical record. It is also recommended that indirect ophthalmoscopy be performed at least once by a qualified ophthalmologist before treatment or termination of acute-phase screening of ROP for infants at risk for ROP. A technical report in which authors have outlined the requirements for a safe program of remote photo screening for ROP has been published by the sponsoring organizations of this policy statement.²³

Digital image capture (taking of retinal photographs) requires skill, experience, broad understanding of the infant eye, and knowledge of ROP (zone, stage, and plus). Ophthalmologists who perform remote interpretation of screening photos for ROP should have the same training requirements as bedside examiners as well as experience in the interpretation of digital images for ROP. Interpretation requires not only expert knowledge about ROP but also understanding of the limitations of interpreting static images and the special care that must be taken to schedule more frequent imaging sessions that may be required because of those limitations. Remote ophthalmologist interpreters must provide timely clinical input on the timing of follow-up imaging sessions and ophthalmoscopic examinations using appropriate methodology. These findings must be communicated in a manner that is compliant with rules of the Health Insurance Portability and Accountability Act (HIPAA) and other federal and state legal requirements.

Digital retinal imaging may also be a useful tool for objective documentation of retinal findings and for teaching NICU staff and parents about examination results, even if it is not the primary method used for ROP screening in the NICU.²⁸

ROP care that includes off-site image interpretation by ophthalmologists requires close collaboration among neonatologists, imaging staff, and examining ophthalmologists. As with all ROP screening programs, specific responsibilities of each individual must be carefully delineated in a protocol written in advance so that repeat imaging and/or confirmatory examinations and required treatments can be performed without delay.

Treatment

• The presence of plus disease (defined as abnormal dilation and tortuosity of the posterior retinal blood vessels in 2 or more quadrants of the retina meeting or exceeding the degree of abnormality represented in reference photographs^1,8; see below) in zones I or II indicates that treatment, rather than observation, is appropriate.^7,13

  • ∘ Treatment should be initiated for the following retinal findings that characterize Type 1 ROP:

    • · Zone I ROP: any stage with plus disease;

    • · Zone I ROP: stage 3, no plus disease; and

    • · Zone II: stage 2 or 3 with plus disease.

• Practitioners involved in the ophthalmologic care of preterm infants should be aware that the presence of the retinal findings requiring strong consideration of ablative treatment were revised according to the Early Treatment of Retinopathy of Prematurity Randomized Trial study.⁷ This recommendation is based on the findings of improved visual outcomes with earlier treatment recommended by the Final Visual Acuity Results in the Early Treatment of Retinopathy of Prematurity Study.²⁹ “Threshold ROP,” a term that refers to specific morphologic features defined in the Multicenter Trial of Cryotherapy for Retinopathy of Prematurity, is no longer the least severe ROP for which intervention should be considered. “Threshold ROP,” as defined in the Multicenter Trial of Cryotherapy for Retinopathy of Prematurity study, is now included in type 1 ROP, as are certain levels of what was previously known as prethreshold disease that also respond better to ablative treatment than to observation.⁷

  • ∘ Special care must be used in determining the zone of disease. The authors of the “International classification of retinopathy of prematurity revisited” provide specific examples on how to identify zone I and zone II disease by using binocular indirect ophthalmoscopy;

  • ∘ As noted previously, the presence of plus disease, rather than the number of clock hours of disease, is the better determining factor in recommending ablative treatment;

  • ∘ Treatment should generally be accomplished as soon as possible, at least within 72 hours of determination of the presence of treatable disease, in order to minimize the risk of retinal detachment; and

  • ∘ Follow-up is recommended in 3 to 7 days after laser photocoagulation or anti-VEGF injection to ensure that there is no need for additional laser treatment in areas where ablative treatment was not complete or additional anti-VEGF injection.

• Anti-VEGF treatment may hold great promise in the treatment of type 1 ROP. Recently published data³⁰ indicate that intravitreal bevacizumab monotherapy, as compared with conventional laser therapy, in infants with stage 3+ ROP is effective in and may offer significantly improved structural results compared with laser ablation for zone I but not for zone II disease. Development of peripheral retinal vessels continues after treatment with intravitreal bevacizumab, whereas conventional laser therapy led to permanent ablation of the peripheral retina, although authors of published studies indicate that this apparent destruction was associated with only a modest visual field loss. This trial³⁰ was too small to assess the safety and effects on future development of the brain and other tissues. Additional studies are also currently being conducted with other anti-VEGF agents, including ranibizumab (Lucentis). Consideration may be given to treatment of infants with zone I, stage 3+ ROP with intravitreal injection of bevacizumab. However, practitioners using this therapy should be aware that neither bevacizumab nor other anti-VEGF substances is currently approved by the US Food and Drug Administration for the treatment of ROP.

  • ∘ If intravitreal injection of bevacizumab or other anti-VEGF agents for zone I stage 3+ ROP is contemplated, it is essential that treatment be administered only after obtaining a detailed informed consent because there remain unanswered questions involving dosage, timing, safety, and visual and systemic outcomes. Whether there are neurodevelopmental complications related to this treatment remains to be seen. To date, studies have yielded contrary findings, with 1 publication^31–33 reporting increased incidence of neurodevelopmental problems, including severe cerebral palsy, hearing loss, and bilateral blindness, in preterm infants treated with bevacizumab compared with infants whose ROP was treated with laser peripheral ablation alone, but another publication revealed no such effect.³⁴ In addition, reports indicate that there might be less myopic progression in infants treated with bevacizumab compared with infants treated with laser ablation, although long-term comparisons between laser and bevacizumab therapy are lacking.^35,36

• Infants treated with bevacizumab injection should be monitored closely after injection by using techniques in accord with these ROP examination guidelines until retinal vascularization is completed or, if not completed, until the examiner can be assured that reactivation of proliferative ROP will not occur. In the BEAT-ROP study,³⁰ recurrence of ROP after bevacizumab injection tended to occur considerably later than after conventional laser peripheral retinal ablative treatment (16 ± 4.6 vs 6.2 ± 5.7 weeks); therefore, longer follow-up is required for infants treated with bevacizumab to ensure that ROP requiring treatment does not recur. Long-term follow-up of the BEAT-ROP cohort revealed the time frame of highest disease reactivation was between 45 and 55 weeks’ postmenstrual age, with 1 AP-ROP case reactivating at 64 weeks’ postmenstrual age.^31,37 There are additional reports^{25,31,35,36,38} of recurrence requiring retreatment as late as 65 to 70 weeks’ postmenstrual age.

  • ∘ Infants treated with intravitreal injection of bevacizumab or ranibizumab alone, therefore, require special caution in the decision to conclude regular retinal examinations. Because of the propensity for late reactivation of significant proliferative disease, one cannot rely on the findings of initial ROP regression or the achievement of 45 weeks’ postmenstrual age. Full retinal vascularization is the only criterion listed above that can be relied on as a valid conclusion point. However, full retinal vascularization is not always achieved in infants treated with these agents alone. Under these circumstances, the examiner will have to rely on prolonged observation, clinical judgment, and evolving criteria in the literature for termination of examinations or a need for further treatment.³

• Communication with parents by members of the care team is important, as is documentation of those communications. Parents should be aware of ROP examinations and should be informed if their child has ROP, with subsequent updates on ROP progression, and should be aware of the possibility of blindness if they do not adhere to the examination schedule after discharge. The possible consequences of serious ROP should be discussed at the time that a significant risk of poor visual outcome develops. Documentation of such conversations with parents in the nurse or physician notes is highly recommended, as is the use of standardized parental educational materials.

• Responsibility for examination and follow-up of infants at risk for ROP must be carefully defined by the staff and consultants of each NICU. Unit-specific criteria with respect to birth weight and gestational age for examination for ROP should be established for each NICU by consultation and agreement between neonatology and ophthalmology services. These criteria should be recorded and should automatically trigger ophthalmologic examinations or photographic documentation with transmission for reading if remote digital camera screening for ROP is used.

Follow-up and Transition of Care

• If hospital discharge or transfer to another neonatal unit or hospital is contemplated before retinal development into anterior zone III has taken place, or if the infant has been treated for ROP and there is either incomplete regression or incomplete retinal healing or maturation, follow-up must be arranged before the infant’s departure from the hospital, including ensuring the availability of appropriate ophthalmologic follow-up; specific arrangement for that examination must be made before such discharge or transfer occurs. The transferring or discharging pediatrician, after consultation with the examining ophthalmologist, has the responsibility for communicating to the receiving physician what eye examinations are needed and their required timing. By review of the medical record and communication with the transferring and/or discharging pediatrician, as appropriate, the receiving physician should ascertain the current ocular examination status of the infant. This period of review and communication before discharge or transfer provides the opportunity for any necessary examinations by an ophthalmologist with ongoing experience and expertise in examination of preterm infants for ROP to be arranged at the appropriate time at the receiving facility or on an outpatient basis if discharge is contemplated before the need for continued examination has ceased, as outlined in recommendation 5 and in the section above on treatment with anti-VEGF agents. For infants managed by using remote photo screening, especially those treated with anti-VEGF agents, outpatient remote photo screening is not currently available. In these cases, examination with indirect ophthalmoscopy is the only option available, and these follow-up examinations must be arranged before discharge.

• It is strongly recommended that the hospital staff arrange and schedule the first postdischarge outpatient ophthalmology appointment with a physician trained in ROP care before the infant’s discharge from the hospital. If responsibility for arranging follow-up ophthalmologic care after discharge is delegated to the parents, they must be made to understand the potential for severe visual loss, including blindness; that there is a critical examination time schedule to be met if treatment is to be successful; and that timely follow-up examination is essential to successful treatment. This information should be communicated both verbally and in writing and should be carefully documented in the infant’s medical record. If such arrangements for communication and follow-up after transfer or discharge cannot be made, the infant should not be discharged until appropriate follow-up examination can be arranged by the unit staff who are discharging the infant.

• Regardless of whether infants at risk develop treatment-requiring ROP, pediatricians and other physicians who care for infants who have had ROP should be aware that these infants are at increased risk for other seemingly unrelated visual disorders, such as strabismus, amblyopia, high refractive errors, cataracts, and glaucoma. Ophthalmologic follow-up for these potential problems after discharge from the NICU is indicated within 4 to 6 months after discharge.

This statement replaces the previous statement on ROP from the American Academy of Pediatrics, American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus, and American Association of Certified Orthoptists³⁹; ROP care is evolving, and recommendations may be modified as additional data about ROP risk factors, treatments, and long-term outcomes are published.